Get the Stockscreener App
7.13
6.10%
0.41
After Hours:
7.15
0.02
+0.28%
Novavax Inc stock is traded at $7.13, with a volume of 3.88M.
It is up +6.10% in the last 24 hours and up +8.03% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
See More
Previous Close:
$6.72
Open:
$6.76
24h Volume:
3.88M
Relative Volume:
0.98
Market Cap:
$1.16B
Revenue:
$1.08B
Net Income/Loss:
$422.82M
P/E Ratio:
3.1272
EPS:
2.28
Net Cash Flow:
$-637.33M
1W Performance:
+4.39%
1M Performance:
+8.03%
6M Performance:
+5.47%
1Y Performance:
-16.80%
1-Day Range:
$6.76
$7.195
1-Week Range:
$6.595
$7.195
52-Week Range:
$5.01
$11.55
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Compare NVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
7.13 | 1.09B | 1.08B | 422.82M | -637.33M | 2.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-28-25 | Resumed | H.C. Wainwright | Buy |
| Aug-20-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-17-25 | Initiated | Citigroup | Sell |
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Novavax stock today: NVAX closes up 6% as Singapore rolls out JN.1 Novavax COVID shot - ts2.tech
Novavax, Inc. (NASDAQ:NVAX) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Novavax (NVAX) Stock Trades Up, Here Is Why - Finviz
Risk Hedge: Is Novavax Inc NVV1 stock undervalued after correctionEarnings Beat & Real-Time Buy Signal Alerts - moha.gov.vn
Aug Analyst Calls: Should I hold or sell Novavax Inc stock in 2025July 2025 Weekly Recap & Stepwise Trade Execution Plans - moha.gov.vn
Novavax (NASDAQ:NVAX) Surprises With Q3 CY2025 Sales - Yahoo Finance
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Novavax (NVAX), Xenon (XENE) and Biohaven Ltd. (BHVN) - The Globe and Mail
Investor Mood: How strong is Novavax Inc stock balance sheetJuly 2025 Chart Watch & Accurate Buy Signal Notifications - moha.gov.vn
NVAX Stock Today: Can Novavax Turn Regulatory Turmoil and Activist Pressure into a Comeback? - ts2.tech
Trading Systems Reacting to (NVAX) Volatility - Stock Traders Daily
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
What valuation multiples suggest for Novavax Inc stockWeekly Gains Report & Weekly Watchlist of Top Performers - moha.gov.vn
Novavax Inc. Stock Underperforms Tuesday When Compared To Competitors - 富途牛牛
Evaluating Novavax’s Current Valuation After Steep Five Year Share Price Collapse - Yahoo Finance
Why Novavax Inc. stock is favored by pension fundsJuly 2025 Final Week & Consistent Profit Trade Alerts - Улправда
Will Novavax Inc. stock gain from strong economyWeekly Profit Recap & Fast Moving Trade Plans - Bölüm Sonu Canavarı
Will Novavax Inc. stock outperform international peersQuarterly Portfolio Review & Weekly Top Gainers Trade List - ulpravda.ru
Interesting NVAX Call Options For February 2026 - Nasdaq
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know - Yahoo Finance
Should I hold or sell Novavax Inc. stock in 2025Trade Performance Summary & Low Risk High Win Rate Picks - DonanımHaber
Why Novavax Inc. stock is trending among retail traders2025 Volume Leaders & Stepwise Entry and Exit Trade Signals - DonanımHaber
Market Trends: Why Novavax Inc. stock remains a top recommendationTrade Volume Report & Verified Stock Trade Ideas - DonanımHaber
What hedge fund activity signals for Novavax Inc. stockWatch List & Free Accurate Trade Setup Notifications - DonanımHaber
Novavax Inc. Stock Outperforms Competitors On Strong Trading Day - 富途牛牛
How strong is Novavax Inc. stock balance sheet2025 Technical Overview & Community Verified Watchlist Alerts - Bölüm Sonu Canavarı
Pfizer leads COVID-19 vaccine peers lower after revamped guidance - Seeking Alpha
VP Casey Acquires 29,186 Of Novavax Inc [NVAX] - TradingView — Track All Markets
Novavax Inc. Stock Underperforms Friday When Compared To Competitors - 富途牛牛
Avoiding Lag: Real-Time Signals in (NVAX) Movement - news.stocktradersdaily.com
Revenue Check: Why Novavax Inc stock is trending among retail traders2025 Top Decliners & Stepwise Swing Trade Plans - moha.gov.vn
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
FDA intends to put most serious warning on COVID vaccines, CNN reports - Reuters
CDC study finds COVID shot significantly reduced ER visits for children - Seeking Alpha
Why I wouldn't touch Novavax with a 10-foot pole - MSN
Why I Wouldn't Touch Novavax With a 10-Foot Pole - Yahoo Finance
Novavax Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Novavax Inc. stock underperforms Monday when compared to competitors - MarketWatch
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock - Yahoo Finance
Lobbying Update: $30,000 of NOVAVAX lobbying was just disclosed - Quiver Quantitative
Novavax, Inc. (NVAX): A Bull Case Theory - Finviz
Novavax, Inc. (NVAX): A bull case theory - MSN
Will Novavax Inc. (NVV1) stock deliver stable dividendsMarket Movement Recap & Verified Technical Signals - Newser
How Novavax Inc. (NVV1) stock benefits from digital adoptionJuly 2025 Action & Weekly Breakout Watchlists - Newser
How Novavax Inc. (NVV1) stock gains from tech spendingRisk Management & Weekly Stock Performance Updates - Newser
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):